Showing 641-650 of 695 results for "".
- Updates on Aesthetic Meeting Cancellations Due to COVID-19https://modernaesthetics.com/news/aesthetic-meeting-cancellation-updates/2472895/In an attempt to help slow the continuing spread of the COVID-19 virus, many industry societies have cancelled or postponed conferences. The Aesthetics Meeting 2020 has postponed its meeting, which was scheduled to start on April 25 in Las Vegas. Find more inforamtion about the postpone
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Candela Launches Exceed Medical Microneedling Systemhttps://modernaesthetics.com/news/candela-launches-exceed-medical-microneedling-system/2472878/Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch
- RealSelf Reveals List of Most Worth It Procedureshttps://modernaesthetics.com/news/realself-reveals-list-of-most-worth-it-procedures/2472877/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Revian: USPTO Grants Patent for Biostimulatory Approachhttps://modernaesthetics.com/news/regina-uspto-grants-patent-for-biostimulatory-approach/2472862/The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the use
- Alastin Skincare Receives Third Patenthttps://modernaesthetics.com/news/elastin-skincare-receives-third-patent/2472853/Alastin Skincare, Inc. has received a third US Patent from the United States Patent and Trademark Office. The patent covers Alastin’s innovative science and products. US Patent No. 10,493,011 is entitled, "Peptide Compositions and Methods for Ameliorating Skin Laxity and Bod
- Lutronic Introduces the Most Powerful Thulium Laser to Receive FDA Clearancehttps://modernaesthetics.com/news/lutronic-introduces-the-most-powerful-thulium-laser-to-receive-fda-clearance/2472852/Lutronic unveiled the new LaseMD ULTRA™ during live patient demonstrations at the Cosmetic Surgery Forum in Nashville, TN. The LaseMD ULTRA offersthe highest available power that allows for fast treatments, customizable for multiple areas. Additionally, the system providesgen
- Cutera Launches Heroes Among Us Programhttps://modernaesthetics.com/news/cutera-launches-heroes-among-us-program/2472851/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical